Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Multicentre French RCT (n=116), which was stopped early, found no difference between the anakinra and usual care group in terms of 4-day improvement, 14-day ventilation requirement or death, and 28-day and 90-day mortality.

Source:

The Lancet Respiratory Medicine